FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1470598344> ?p ?o ?g. }

• W1470598344 endingPage "1894" @default.
• W1470598344 startingPage "1889" @default.
• W1470598344 abstract "There are limited treatment options for patients with recurrent glioblastoma (GBM). The EnGeneIC delivery vehicle (EDV) is a novel nanocellular (minicell) compound which packages theoretically effective concentrations of chemotherapeutic drugs that are designed to target tumors via minicell-surface attached bispecific proteins (EnGeneIC, Lane Cove West, NSW, Australia). Epidermal growth factor receptor (EGFR) is overexpressed in 40-50% of patients with GBM and is a promising target for new therapeutics. (V)EDVDox contains doxorubicin (Dox) within the minicells and targets EGFR through Vectibix (V; Amgen Biologicals, Thousand Oaks, CA, USA). We conducted a first in human Phase I study of (V)EDVDox in adults with recurrent GBM expressing EGFR on immunohistochemistry, following standard therapy including radiation and temozolomide, to establish a safe maximum tolerated dose and determine a recommended Phase II dose (RPTD). (V)EDVDox was administered weekly in an 8week cycle, with dose escalation in successive cohorts of patients using a standard 3+3 design. In total, 14 patients were treated at three dose levels, and the RPTD was identified as 5×10(9)(V)EDVDox. Overall (V)EDVDox was well tolerated, with no dose limiting toxicity and no withdrawals from the study due to adverse events. The most common adverse events were nausea, fever, and chills or rigors, experienced in seven, five and five patients, respectively. Transient uncomplicated hypophosphatemia was seen in seven patients and was not dose-related. Our results demonstrate that (V)EDVDox, up to a dose of 5×10(9)(V)EDVDox weekly, is well tolerated in patients with recurrent GBM." @default.
• W1470598344 created "2016-06-24" @default.
• W1470598344 creator A5010378038 @default.
• W1470598344 creator A5010759705 @default.
• W1470598344 creator A5034737796 @default.
• W1470598344 creator A5038506293 @default.
• W1470598344 creator A5045959942 @default.
• W1470598344 creator A5081680405 @default.
• W1470598344 creator A5085923503 @default.
• W1470598344 creator A5087036316 @default.
• W1470598344 creator A5091652642 @default.
• W1470598344 date "2015-12-01" @default.
• W1470598344 modified "2023-10-12" @default.
• W1470598344 title "First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma" @default.
• W1470598344 cites W1858161324 @default.
• W1470598344 cites W1963558982 @default.
• W1470598344 cites W1969949951 @default.
• W1470598344 cites W1978516071 @default.
• W1470598344 cites W1992457036 @default.
• W1470598344 cites W1996719014 @default.
• W1470598344 cites W1999088373 @default.
• W1470598344 cites W2012940399 @default.
• W1470598344 cites W2029409133 @default.
• W1470598344 cites W2036044314 @default.
• W1470598344 cites W2036254354 @default.
• W1470598344 cites W2043023811 @default.
• W1470598344 cites W2048260140 @default.
• W1470598344 cites W2070705072 @default.
• W1470598344 cites W2081215365 @default.
• W1470598344 cites W2082133979 @default.
• W1470598344 cites W2087855239 @default.
• W1470598344 cites W2117941094 @default.
• W1470598344 cites W2122410048 @default.
• W1470598344 cites W2132697290 @default.
• W1470598344 cites W2134989772 @default.
• W1470598344 cites W2143476979 @default.
• W1470598344 cites W2148977460 @default.
• W1470598344 cites W2160137787 @default.
• W1470598344 cites W2162643152 @default.
• W1470598344 cites W2167610854 @default.
• W1470598344 cites W2415933339 @default.
• W1470598344 cites W4211190847 @default.
• W1470598344 doi "https://doi.org/10.1016/j.jocn.2015.06.005" @default.
• W1470598344 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26279503" @default.
• W1470598344 hasPublicationYear "2015" @default.
• W1470598344 type Work @default.
• W1470598344 sameAs 1470598344 @default.
• W1470598344 citedByCount "79" @default.
• W1470598344 countsByYear W14705983442015 @default.
• W1470598344 countsByYear W14705983442016 @default.
• W1470598344 countsByYear W14705983442017 @default.
• W1470598344 countsByYear W14705983442018 @default.
• W1470598344 countsByYear W14705983442019 @default.
• W1470598344 countsByYear W14705983442020 @default.
• W1470598344 countsByYear W14705983442021 @default.
• W1470598344 countsByYear W14705983442022 @default.
• W1470598344 countsByYear W14705983442023 @default.
• W1470598344 crossrefType "journal-article" @default.
• W1470598344 hasAuthorship W1470598344A5010378038 @default.
• W1470598344 hasAuthorship W1470598344A5010759705 @default.
• W1470598344 hasAuthorship W1470598344A5034737796 @default.
• W1470598344 hasAuthorship W1470598344A5038506293 @default.
• W1470598344 hasAuthorship W1470598344A5045959942 @default.
• W1470598344 hasAuthorship W1470598344A5081680405 @default.
• W1470598344 hasAuthorship W1470598344A5085923503 @default.
• W1470598344 hasAuthorship W1470598344A5087036316 @default.
• W1470598344 hasAuthorship W1470598344A5091652642 @default.
• W1470598344 hasConcept C121608353 @default.
• W1470598344 hasConcept C126322002 @default.
• W1470598344 hasConcept C143998085 @default.
• W1470598344 hasConcept C197934379 @default.
• W1470598344 hasConcept C2776694085 @default.
• W1470598344 hasConcept C2777389519 @default.
• W1470598344 hasConcept C2778594517 @default.
• W1470598344 hasConcept C2779438470 @default.
• W1470598344 hasConcept C2780580376 @default.
• W1470598344 hasConcept C2781303535 @default.
• W1470598344 hasConcept C29730261 @default.
• W1470598344 hasConcept C71924100 @default.
• W1470598344 hasConcept C98274493 @default.
• W1470598344 hasConceptScore W1470598344C121608353 @default.
• W1470598344 hasConceptScore W1470598344C126322002 @default.
• W1470598344 hasConceptScore W1470598344C143998085 @default.
• W1470598344 hasConceptScore W1470598344C197934379 @default.
• W1470598344 hasConceptScore W1470598344C2776694085 @default.
• W1470598344 hasConceptScore W1470598344C2777389519 @default.
• W1470598344 hasConceptScore W1470598344C2778594517 @default.
• W1470598344 hasConceptScore W1470598344C2779438470 @default.
• W1470598344 hasConceptScore W1470598344C2780580376 @default.
• W1470598344 hasConceptScore W1470598344C2781303535 @default.
• W1470598344 hasConceptScore W1470598344C29730261 @default.
• W1470598344 hasConceptScore W1470598344C71924100 @default.
• W1470598344 hasConceptScore W1470598344C98274493 @default.
• W1470598344 hasIssue "12" @default.
• W1470598344 hasLocation W14705983441 @default.
• W1470598344 hasLocation W14705983442 @default.
• W1470598344 hasOpenAccess W1470598344 @default.
• W1470598344 hasPrimaryLocation W14705983441 @default.

• next